This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.
- Topical Local treatment of primary and secondary bacterial skin infections including impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds/burns.
- Ophth: Treatment of superficial eye infections.
Inhibits bacterial protein synthesis.
- Resolution of localized bacterial infections.
- Not active against Gram-negative organisms; active against Staphylococci, Streptococci and Corynebacterium.
Distribution: Systemically absorbed drug crosses the placenta and enters breast milk.
Metabolism and Excretion: Absorbed drug is extensively metabolized.
Half-life: 5–6 hr.
- Hypersensitivity to fusidic acid or other components of the formulation (topical ointment contains lanolin).
Use Cautiously in:
- OB: Potential benefits should be weighed against the possible hazards to the fetus (crosses the placenta);
- Lactation: Safe use during breast feeding has not been established (enters breast milk).
Adverse Reactions/Side Effects
Derm: mild local irritation
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Topical (Adults and Children) Apply to affected area 3–4 times daily.
Ophth: (Adults and Children) One drop into conjunctival sac of both eyes every 12 hr for 7 days.
Topical cream: 2% (20 mg/g)
Topical ointment (contains lanolin): 2% (20 mg/g)
Ophthalmic viscous drops (microcrystalline suspension): 1%
In Combination with: hydrocortisone (Fucidin H)
- Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.
- Do not confuse topical product with ophthalmic product.
- Topical Consult health care professional for proper cleansing technique before applying medication. Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by health care professional.
- Ophth: Administer 1 drop into conjunctival sac of both eyes every 12 hr for 7 days. See medication administration techniques for instructions.
- Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes.
- Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
Resolution of skin or eye infection.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Complete Product Information.